Company Encyclopedia
View More
name
EXTRAWELL PHAR
00858.HK
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sell of pharmaceutical products in the People’s Republic of China and Hong Kong. The company manufactures transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing; and ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. It is also involved in marketing and distribution of imported pharmaceutical products, including Skin-Cap for the treatment of itching, irritation, redness, and scaly skin issues; and Millibar for the treatment of high blood pressure. In addition, the company develops oral insulin product, which is in clinical trial stage for the treatment of diabetes.
1.450 T
00858.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking44/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-32.05%E
    • Profit Margin-642.07%E
    • Gross Margin43.81%B
  • Growth ScoreE
    • Revenue YoY-11.89%E
    • Net Profit YoY-292.37%E
    • Total Assets YoY-21.54%E
    • Net Assets YoY-26.56%E
  • Cash ScoreD
    • Cash Flow Margin-15.57%D
    • OCF YoY-11.89%E
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreA
    • Gearing Ratio18.64%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "Performance" EXTRAWELL PHAR reported a mid-term loss of 460 million yuan, turning from profit to loss

    EXTRAWELL PHAR announced its interim results for the six months ending in September, with revenue of 28.01 million yuan, a year-on-year decrease of 9%. It recorded a loss of 460 million yuan, compared to a net profit of 101 million yuan in the same period last year, turning from profit to loss; the loss per share was 19.09 cents. No dividend was declared

    AASTOCKS·
    HK
    00858
    -2.41%
    AASTOCKS·
    HK
    00858
    -2.41%

    EXTRAWELL PHAR completed the placement of a total of 160 million shares

    EXTRAWELL PHAR completed the placement of 160 million new shares at an issue price of HKD 0.097 per share. The board discussed diversifying its business and plans to expand into the health supplement market, benefiting from an aging population and the increase in chronic diseases. The new business will synergize with the existing manufacturing and distribution network, with an expected 70% of funds allocated for startup costs and 30% for working capital to support expansion before the end of 2027. This move will complement the core pharmaceutical business and open up sustainable revenue sources

    Zhitong·
    HK
    00858
    -2.41%
    Zhitong·
    HK
    00858
    -2.41%

    EXTRAWELL PHAR plans to issue a total of 160 million shares, with net proceeds used for new business development

    EXTRAWELL PHAR announced plans to issue 160 million shares, with net proceeds to be used for new business development. The company has signed subscription agreements with three subscribers, raising a total of HKD 2.91 million, HKD 1.94 million, and HKD 10.67 million, with a subscription price of HKD 0.097 per share. The funds raised will be used to expand the trade, manufacturing, sales, and distribution of health care products, equipment, and technology in both the Chinese and overseas markets. The company expects that demand in the health care industry will continue to grow with the aging population and increasing health awareness

    Zhitong·
    HK
    00858
    -2.41%
    Zhitong·
    HK
    00858
    -2.41%

    "Performance" EXTRAWELL PHAR achieved a net profit of 223 million yuan for the year, turning losses into profits

    EXTRAWELL PHAR announced its financial results for the fiscal year ending in March, with revenue of 55.43 million yuan, a year-on-year decrease of 6.2%. It recorded a net profit of 223 million yuan, compared to a loss of 163 million yuan in the previous year, turning from loss to profit; earnings per share were 9.32 cents. No final dividend was declared

    AASTOCKS·
    HK
    00858
    -2.41%
    AASTOCKS·
    HK
    00858
    -2.41%

    EXTRAWELL PHAR announced its annual performance, with profit attributable to shareholders of approximately HKD 223 million, turning a profit compared to the same period last year

    According to the Zhitong Finance APP, EXTRAWELL PHAR announced its annual performance for the year ending March 31, 2025, with revenue from continuing operations of HKD 55.429 million, a year-on-year decrease of 6.21%; the profit attributable to the company's owners was approximately HKD 223 million, turning from a loss to a profit year-on-year; basic earnings per share were HKD 0.0932. The announcement stated that the decrease in revenue was mainly due to intensified market competition leading to a decline in sales, slight price adjustments, and changes in the sales mix

    Zhitong·
    HK
    00858
    -2.41%
    Zhitong·
    HK
    00858
    -2.41%
    © 2025 Longbridge｜Disclaimer